PD1-4: United in fight against prostate cancer registry (UFO): a post hoc analysis of secondary interim result in Taiwan
  • 2019-06-27,
  • 上傳者: TUA人資客服組,
  •  0
蒲永孝1、張延驊2、吳東霖3蔡育賢4、Marxengel Asinas-Tan5
台灣大學附設醫院 泌尿科;台北榮民總醫院 泌尿科;高雄榮民總醫院 泌尿科;成功大學醫學院附設醫院 泌尿科;台灣楊森
United in fight against prostate cancer registry (UFO): a post hoc analysis of secondary interim result in Taiwan
Yeong-Shiau Pu1, Yen-Hwa Chang2, Tong-Lin Wu3, Yuh-Shyan Tsai4, Marxengel Asinas-Tan5
Department of Urology1, National Taiwan University Hospital, Taipei, Taiwan; Taipei Veterans General Hospital2, Taiwan; Division of Urology3, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; Department of Urology4, College of Medicine and Hospital, National Cheng Kung University, Tainan, Taiwan
Janssen Taiwan5
The prostate cancer (PC) registry (UFO) has been established with the objective of providing a comprehensive picture of PC diagnosis, prognosis, treatments and outcomes in Asian countries. This is a post hoc analysis of the second interim result of Taiwan’s subpopulation of patients enrolled in the UFO study, which also includes patient-reported treatment outcomes and underlying considerations for clinical decision-making.
Materials and Methods:
UFO study is a large multi-national, observational registry of prostate cancer patients in tertiary care hospitals in eight Asia countries; patients enrolled are high-risk localized PC (HRL), non-metastatic PC (M0) and metastatic PC (M1). This post hoc analysis focuses on the cohort profiles and treatment patterns of Taiwan’s patients with metastatic hormone-sensitive, or metastatic castration-resistant prostate cancer who were followed up from September 2015 until the cut-off period of July 2018.
In Taiwan, 421 eligible patients were enrolled in the second interim analysis: 41 (9.7%), 60 (14.3%), and 320 (76%) had HRL, M0 or M1 PC. Among M1 patients, 201 (62.8%) were diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC) and 119 (37.2%) with metastatic castration-resistant prostate cancer (mCRPC). The median PSA in M1 patients at first confirmed diagnosis is 793.2 ng/ml and 139.1 ng/ml at enrollment. In the meanwhile, 73.6 % of patients had at least one comorbidity; mainly cardiovascular disease. The treatment sequencing including the use of combined androgen blockade, androgen deprivation therapy or chemo therapy at the early stage of mHSPC and mCRPC is also shown. It is found that disease progression, treatment guidelines and patients’ preference were the main reasons for treatment initiation or discontinuation.
This is the first registry study of prostate cancer in Taiwan. Treatment patterns in this study reflect the real-world practice and clinical considerations in Taiwan.  
訪客如要回應,請先 登入
    資料夾 :
    發表時間 :
    2019-06-27 19:36:42
    觀看數 :
    發表人 :
    部門 :
    QR Code :